GH1 and urogenital neoplasm: Besides IGF1R, targeted deletion of hepatic igf1 in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model could lead to dramatic alterations in the circulating IGF axis, but does not reduce tumor progression, which may require a reduction in GH levels as well 37, 38.